Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Hernandez-Ilizaliturri on CAR T-Cell Therapy vs Bispecific Antibodies in DLBCL

August 6th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses deciding between CAR T-cell therapies or approved bispecific antibodies for diffuse large B-cell lymphoma.

Outpatient Treatment With Subcutaneous Epcoritamab Shows Feasibility in R/R DLBCL and Follicular Lymphoma

August 5th 2024

Subcutaneous epcoritamab demonstrated safety when given in the outpatient setting in relapsed/refractory diffuse large B-cell and follicular lymphoma.

FDA Requests Additional Demonstration of OS Benefit to Support Iomab-B BLA in R/R AML

August 5th 2024

The FDA is requiring an additional trial demonstrating an OS benefit with Iomab-B to support the planned filing of the biologics license application for the agent.

Alemtuzumab Earns FDA Orphan Drug Designation for Lymphodepletion Before UCART22 in R/R B-ALL

August 2nd 2024

Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Munir on Cost and QOL Outcomes With Zanubrutinib vs Acalabrutinib in B-Cell Malignancies

August 2nd 2024

Talha Munir, MBChB, PhD, discusses an adverse effect–based economic analysis of zanubrutinib vs acalabrutinib in patients with B-cell malignancies.

Dr Rijneveld on the Addition of Blinatumomab to Prephase and Consolidation Therapy in B-ALL

August 1st 2024

Anita Rijneveld, MD, discusses outcomes with the addition of blinatumomab to prephase and consolidation therapy for patients with adult B-cell acute lymphoblastic leukemia.

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

August 1st 2024

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.

Dr Platzbecker on First-Line ATRA/ATO in High-Risk Acute Promyelocytic Leukemia

July 31st 2024

Uwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.

AYA ALL: Overview and Risk Stratification

July 31st 2024

Experts on acute lymphoblastic leukemia share their clinical experiences, describe high-risk features, and provide insights on risk stratification practices.

Clinical Scenario: A 23-Year-Old Male with AYA ALL

July 31st 2024

A panel of experts from Atrium Health Levine Cancer Institute present a patient case and provide an overview of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL).

Asciminib Receives FDA Priority Review for Newly Diagnosed Ph+ CP-CML

July 30th 2024

The FDA has granted priority review to asciminib for newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Dr Pollyea on the Mechanism of Revumenib in KMT2A-Rearranged R/R AML

July 30th 2024

Dan Pollyea, MD, MS, discusses the mechanism of action for the menin inhibitor revumenib in KMT2A-rearranged relapsed/refractory acute myeloid leukemia.

FDA Extends PDUFA Date for Revumenib in KMT2A-Rearranged Acute Leukemia

July 29th 2024

The FDA has extended the PDUFA date for the NDA seeking the approval of revumenib for patients with relapsed/refractory KMT2A-rearranged acute leukemia.

Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL

July 24th 2024

Blinatumomab added to consolidation chemotherapy led to a significant OS benefit in MRD-negative B-cell precursor acute lymphoblastic leukemia.

Dr Watts on the Investigation of INCB057643 in Advanced Myelofibrosis and MPN

July 24th 2024

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia

July 23rd 2024

Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.

FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

July 23rd 2024

The FDA has accepted the resubmission of a BLA for remestemcel-L in pediatric steroid-refractory acute graft-vs-host-disease.

Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium

July 23rd 2024

A Phase 1b study (NCT03013998) to determine the safety and recommended dose of Revumenib combined with Aza/Ven in patients with newly diagnosed AML ≥ 60 years old with NPM1mut or KMT2Ar and who are not candidates or do not wish to pursue intensive induction therapy.

Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

July 22nd 2024

Justin M. Watts, MD, discusses 5-year efficacy and safety data for olutasidenib in IDH1-mutant, relapsed/refractory AML.

Dr Shadman on the Evaluation of Zanbrutinib Plus Sonrotoclax in Treatment-Naive CLL

July 22nd 2024

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.